focus -WSS

focus

author：knowledge 2025-09-28 23:11:52 - browse：82845

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

entertainment

WSS

Community Health Systems hospitals under DOJ investigation

Trial using CRISPR to edit HIV out of cells disappoints

Multiple sclerosis has subtypes with different best treatments: study

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Pancreatic cancer is often deadly, but new discoveries are raising hope

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

entertainment

Heart attack and stroke risk calculators need revising

Alabama hospital puts IVF treatments on hold

Apple is now the first public company to be valued at $3 trillion

Alabama frozen embryo ruling has major implications for IVF clinics

New air purifier tech could be key to improving indoor air quality

Bird flu in dairy cattle: New measures to control spread to humans

Bright Health sells Medicare Advantage business to Molina

Obesity drugs seen as possible treatment for liver disease MASH

Anesthesiologist group: stop taking Ozempic before surgery

Antivenom research: Lessons from HIV applied in search for universal antidote

entertainment

Ed Silverman on new gene therapies, biosimilars, coffee, and more

First Opinion on colorectal cancer screening: letter and response

Dario to buy mental health app maker Twill in cash and stock deal

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

PBM reform efforts get punted in Congress

U.K. decision on ALS drug has neurologists, advocates up in arms

hotspot

leisure time

entertainment

focus